Mineralys Therapeutics (MLYS) reported a Q3 net loss late Monday of $1.13 per diluted share, widening from $0.57 a year earlier.
Analysts polled by Capital IQ expected a loss of $0.83.
Cash, cash equivalents and investments as of Sept. 30 were $263.6 million, up from $239 million as of Dec. 31, 2023.
Mineralys said it expects current cash, cash equivalents and investments to fund clinical trials and corporate operations into 2026.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。